$1,318.00
This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Chemotherapy
9 Radiotherapy
9 Immunotherapy
10 Surgery
10 Palliative procedures
11 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Tiragolumab for SCLC (March 29, 2022)
25 Zepzelca for SCLC (December 3, 2020)
28 KEY UPCOMING EVENTS
29 KEY REGULATORY EVENTS
29 MNCs Seek Indication Expansions
30 PROBABILITY OF SUCCESS
31 LICENSING AND ASSET ACQUISITION DEALS
31 Hyloris Announces Partnership With Pleco Therapeutics
31 Lotus Picks Up Rights To PharmaMar Cancer Drug In Taiwan
32 REVENUE OPPORTUNITY
34 CLINICAL TRIAL LANDSCAPE
35 Sponsors by status
36 Sponsors by phase
37 Recent events
38 BIBLIOGRAPHY
39 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in incident cases of SCLC, 2019–28
17 Figure 2: Overview of pipeline drugs for SCLC in the US
17 Figure 3: Pipeline drugs for SCLC, by company
18 Figure 4: Pipeline drugs for SCLC, by drug type
18 Figure 5: Pipeline drugs for SCLC, by classification
27 Figure 6: Zepzelca for SCLC (December 3, 2020): Phase III – ATLANTIS (w/Doxorubicin)
28 Figure 7: Key upcoming events in SCLC
30 Figure 8: Probability of success in the solid tumors pipeline
34 Figure 9: Clinical trials in SCLC
34 Figure 10: Top 10 drugs for clinical trials in SCLC
35 Figure 11: Top 10 companies for clinical trials in SCLC
35 Figure 12: Trial locations in SCLC
36 Figure 13: SCLC trials status
37 Figure 14: SCLC trial sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of SCLC, 2019–28
13 Table 2: Incidence rates of SCLC
15 Table 3: Marketed drugs for SCLC
19 Table 4: Pipeline drugs for SCLC in the US
25 Table 5: Tiragolumab for SCLC (March 29, 2022)
26 Table 6: Zepzelca for SCLC (December 3, 2020)
32 Table 7: Historical global sales, by drug ($m), 2017–21
33 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!